Solid Tumor (Phase I)
Conditions
Keywords
ABSK211, KRAS Alteration
Brief summary
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
Detailed description
The study will start with a dose escalation of oral ABSK211 in participants with advanced solid tumors with KRAS alteration to evaluate safety, tolerability, and PK. The expansion part will evaluate the safety and efficacy of oral ABSK211 at the recommended doses for expansion (RDEs) in selected tumor types harboring KRAS alteration and further optimize the dosage.
Interventions
DRUGABSK211
During the escalation part ,all participants will firstly receive a single dose of ABSK211 as a run-in period to access the safety and PK of ABSK211. Then, participants will continuously receive ABSK211 once daily (QD), with each treatment cycle of 21 days； In the expansion part，participants will orally receive ABSK211 at the recommended dose for expansion (RDE).
Sponsors
Abbisko Therapeutics Co, Ltd
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants should understand, sign, and date the written informed consent form prior to screening. 2. Male or female age 18 years or older 3. Participants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration 4. ECOG performance status 0 or 1 5. Life expectancy ≥ 3 months 6. Adequate organ function and bone marrow function 7. For participants participating exploration of food effect: 1)be able to eat a standardized high-fat, high caloric meal within 30 minutes. 2) be able to fast for 10 hours.
Exclusion criteria
1. Known allergy or hypersensitivity to any component of the investigational product 2. Participants who were previously treated with any inhibitors targeting specific KRAS alleles, pan-KRAS inhibitors, pan- or multi-RAS inhibitors, or any other treatments directly targeting RAS. 3. Has a known additional malignancy that is progressing or has required active treatment 4. Has swallowing dysfunction or malabsorption syndrome 5. Previous anti-tumor therapy, including chemotherapy ,endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life ,radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment. 6. Major surgery within 4 weeks of the first dose of investigational product or with any unhealed surgical wounds, infection or dehiscence. 7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity; 8. Participants use proton pump inhibitors for at least 7 days prior to the first dose of ABSK211 and during treatment with ABSK211. 9. P-gp inhibitor, moderate and strong CYP3A inhibitors to 7 days or 5 half-lives and for strong CYP3A inducers to 2 weeks or 5 half-lives ; 10. Active central nervous system (CNS) metastases; 11. History of interstitial lung disease (ILD) requiring systemic steroid treatment; 12. Heart disease or medical history ; 13. NSCLC cohorts: Participant previously identified as having a driver mutation and have not received any targeted therapy; 14. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1/2 antibody; 15. Exclusion of hepatitis infection; 16. Participants with refractory/uncontrolled ascites or pleural effusion; 17. Pregnant or nursing (lactating) women; 18. Partners of non-surgically sterilized male participants or female participants of childbearing potential who refuse to use effective methods of birth control during the study and for up to 6 months after the last dose of investigational product; 19. Sexually active males who refuse to use a condom during medication period and until 3 months after stopping investigational product; 20. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines ; 21. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition; \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SAEs | The date of signing the informed consent form until 30 days (including Day 30) after the last administration of investigational product | Serious adverse events (SAEs) |
| Incidence of DLTs | from Run-in to Day21 | dose-limiting toxicities |
| AEs | The date of signing the informed consent form until 30 days (including Day 30) after the last administration of investigational product | Adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax | from pre-dose to up to 72 hours post-dose | time to maximum observed concentration |
| AUC | from pre-dose to up to 72 hours post-dose | area under the concentration-time curve |
| t1/2 | from pre-dose to up to 72 hours post-dose | elimination half-life |
| CL/F | from pre-dose to up to 72 hours post-dose | apparent oral clearance |
| ORR | throughout study completion, assessed up to 24 months | Objective response rate |
| DOR | throughout study completion, assessed up to 24 months | Duration of response |
| DCR | throughout study completion, assessed up to 24 months | Disease control rate |
| PFS | throughout study completion, assessed up to 24 months | Progression-free survival |
| OS | throughout study completion, assessed up to 24 months | Overall survival |
| AR | from pre-dose to up to 72 hours post-dose | accumulation ratio |
| Vz/F | from pre-dose to up to 72 hours post-dose | apparent volume of distribution |
| BPR | from pre-dose to up to 72 hours post-dose | Blood plasma ratio |
| Cmax | from pre-dose to up to 72 hours post-dose | maximum observed concentration |
Countries
China
Contacts
CONTACTLijun Zheng, Master
CONTACTJiaojuan He, Master
PRINCIPAL_INVESTIGATORXianjun Yu, Doctor
Fudan University
Outcome results
None listed